Journal of Hepatology
Volume 51, Issue 4 , Pages 787-791 , October 2009

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B

  • Russell D. Fleischer

      Affiliations

    • Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
    • ,
  • Anna S.F. Lok

      Affiliations

    • Division of Gastroenterology and Hepatology, University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Fax: +1 734 9367392.

References 

  1. Kim BK, Oh J, Kwon BK, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51:829–834
  2. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49:2080–2086
  3. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099–1105
  4. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, et al. Preclinical investigation of l-FMAU as an anti-hepatitis B virus agent. Antivir Ther. 1998;3:S113–S121
  5. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2:812–822
  6. Wang J, Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-beta-d-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 1996;40:1555–1557
  7. Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging. 2008;35:1480–1488
  8. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15–22
  9. Bading JR, Shahinian AH, Bathija P, Conti PS. Pharmacokinetics of the thymidine analog 2′-fluoro-5-[(14)C]-methyl-1-beta-d-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. Nucl Med Biol. 2000;27:361–368
  10. Colacino JM, Malcolm SK, Jaskunas SR. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother. 1994;38:1997–2002
  11. Cui L, Yoon S, Schinazi RF, Sommadossi JP. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-d-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest. 1995;95:555–563
  12. Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1282–1292
  13. Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, Bronowicki JP, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology. 2004;40:140–148
  14. Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006;50:1642–1648
  15. Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006;43:982–988
  16. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46:1041–1048
  17. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45:1172–1178
  18. Bowsher RR, Compton JA, Kirkwood JA, Place GD, Jones CD, Mabry TE, et al. Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrob Agents Chemother. 1994;38:2134–2142
  19. Richardson FC, Engelhardt JA, Bowsher RR. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci USA. 1994;91:12003–12007
  20. Lok AS, Wilson LA, Thomas HC. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J Antimicrob Chemother. 1984;14:93–99
  21. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495
  22. Avila C, Laeufle R, Bao W. CK elevation during chronic hepatitis B (CHB) treatment with telbivudine: experience from the combined globe (NV-02B-007/CLDT600A2302) and NV-02B-015 (015) study clinical safety database. In: Poster #PE 140 presented at the 19th asian pacific association for the study of the liver (APASL); February 13–16, 2009, Hong Kong; 2009.
  23. Goncalves J, Laeufle R, Avila C. Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the novartis global database. J Hepatol. 2009;50:S329;Abstract #907
  24. Weaver M, Wolf A, Persohn E, Grenet O, Pognan F, Dong M. Absence of Mitochondrial toxicity of telbuvidine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human. In: Abstract from the 19th asian pacific association for the study of the liver (APASL); February 13–16, 2009, Hong Kong; 2009.
  25. Garcia G, Smith CI, Weissberg JI, Eisenberg M, Bissett J, Nair PV, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med. 1987;107:278–285
  26. Yahagi K, Ueno Y, Mano Y, Shimosegawa T. Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl. 2002;8:1198–1199
  27. Adani GL, Baccarani U, Risaliti A, Bresadola F, Della Rocca G, Viale P. Rhabdomyolysis due to lamivudine administration in a liver transplant recipient. Am J Transplant. 2005;5:634
  28. Marcellin P, Chang T, Lim SG, Tong M, Sievert W, Schiffman M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  29. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273–1281
  30. Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751

☆ R.D.F. declared that he does not have anything to disclose regarding funding or conflict of interest with respect to this manuscript. A.S.F.L. receives research support from Bristol-Myers Squibb, GlaxoSmithKline, Schering, Novartis and Gilead and serves as an advisor for Gilead, Pharamasset, Schering and Roche.

PII: S0168-8278(09)00453-X

doi: 10.1016/j.jhep.2009.06.011

Journal of Hepatology
Volume 51, Issue 4 , Pages 787-791 , October 2009

Article Tools